PacBio Q4 revenue $44.6M, consumable record; GAAP net loss $40.4M, non-GAAP loss narrows

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

2025-FY EPS reported -$1.82 revenue$160,005,000

Q4 revenue $44.6M (+14% YoY); consumable revenue record $21.6M (+15% YoY).
GAAP net loss $40.4M ($0.13/share) vs GAAP net income $2.4M in Q4 2024 (incl $154.4M debt restructuring gain).
Non-GAAP net loss $37.6M ($0.12/share) vs $55.3M ($0.20) in Q4 2024; non-GAAP gross margin 40% vs 31%.
Vega placements 42 in Q4 (140 FY); Revio placements 21 Q4 (61 FY). Annualized Revio pull-through ~$242,000.
Completed sale of short-read assets for ~$48.1M net cash; cash & investments $279.5M at year end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.